Global WholeHealth Partners Corp (OTC: GWHP) to Announce that Global is Now Offering All 4 Major Vaccines (AstraZeneca, J&J, Pfizer, Moderna) as Mentioned in 8k Filings 03/08/21, 06/09/21, 06/15/21, and 06/24/21
August 09, 2021 07:00 ET
|
Global WholeHealth Partners Corp.
The Vaccines Have Been Verified to Assist in the Protection Against the Delta Variant SAN CLEMENTE, CA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp...
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET
|
Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
July 08, 2021 08:00 ET
|
F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
Global Protein Tyrosine Kinase 7 Market is estimated with a CAGR of 5.8% during the forecast period - by PMI
June 10, 2021 10:35 ET
|
PMI
Covina, CA, June 10, 2021 (GLOBE NEWSWIRE) -- The global protein tyrosine kinase 7 market is anticipated to register a CAGR of 5.8%. Tyrosine-protein kinase-like 7, also known as colon carcinoma...
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
May 26, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma...
Global Cancer ALK Inhibitor Market is estimated to be US$ 10.6 billion by 2030 with a CAGR of 22.0% during the forecast period - by PMI
April 16, 2021 10:05 ET
|
PMI
Covina, CA, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to...
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
March 29, 2021 08:30 ET
|
Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm
March 26, 2021 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 23, 2021 09:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
March 22, 2021 21:00 ET
|
Dyadic International, Inc.
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two...